309 related articles for article (PubMed ID: 21256157)
1. Drug discovery and the human kinome: recent trends.
Eglen R; Reisine T
Pharmacol Ther; 2011 May; 130(2):144-56. PubMed ID: 21256157
[TBL] [Abstract][Full Text] [Related]
2. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
[TBL] [Abstract][Full Text] [Related]
3. Strategies for the selective regulation of kinases with allosteric modulators: exploiting exclusive structural features.
Fang Z; Grütter C; Rauh D
ACS Chem Biol; 2013 Jan; 8(1):58-70. PubMed ID: 23249378
[TBL] [Abstract][Full Text] [Related]
4. Direct small-molecule kinase activation: Novel approaches for a new era of drug discovery.
Simpson GL; Hughes JA; Washio Y; Bertrand SM
Curr Opin Drug Discov Devel; 2009 Sep; 12(5):585-96. PubMed ID: 19736618
[TBL] [Abstract][Full Text] [Related]
5. Blocking the mTOR pathway: a drug discovery perspective.
Garcia-Echeverria C
Biochem Soc Trans; 2011 Apr; 39(2):451-5. PubMed ID: 21428918
[TBL] [Abstract][Full Text] [Related]
6. Design strategies for protein kinase inhibitors.
Parang K; Sun G
Curr Opin Drug Discov Devel; 2004 Sep; 7(5):617-29. PubMed ID: 15503864
[TBL] [Abstract][Full Text] [Related]
7. Fluorescence labels in kinases: a high-throughput kinase binding assay for the identification of DFG-out binding ligands.
Simard JR; Rauh D
Methods Mol Biol; 2012; 800():95-117. PubMed ID: 21964785
[TBL] [Abstract][Full Text] [Related]
8. Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of protein kinases.
Cox KJ; Shomin CD; Ghosh I
Future Med Chem; 2011 Jan; 3(1):29-43. PubMed ID: 21428824
[TBL] [Abstract][Full Text] [Related]
9. Proteus in the world of proteins: conformational changes in protein kinases.
Rabiller M; Getlik M; Klüter S; Richters A; Tückmantel S; Simard JR; Rauh D
Arch Pharm (Weinheim); 2010 Apr; 343(4):193-206. PubMed ID: 20336692
[TBL] [Abstract][Full Text] [Related]
10. High-throughput screening for kinase inhibitors.
von Ahsen O; Bömer U
Chembiochem; 2005 Mar; 6(3):481-90. PubMed ID: 15742384
[TBL] [Abstract][Full Text] [Related]
11. A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
Gao Y; Davies SP; Augustin M; Woodward A; Patel UA; Kovelman R; Harvey KJ
Biochem J; 2013 Apr; 451(2):313-28. PubMed ID: 23398362
[TBL] [Abstract][Full Text] [Related]
12. Leveraging Structural Diversity and Allosteric Regulatory Mechanisms of Protein Kinases in the Discovery of Small Molecule Inhibitors.
Verkhivker GM
Curr Med Chem; 2017; 24(42):4838-4872. PubMed ID: 27719654
[TBL] [Abstract][Full Text] [Related]
13. Allosteric approaches to the targeting of G-protein-coupled receptors for novel drug discovery: a critical assessment.
Raddatz R; Schaffhauser H; Marino MJ
Biochem Pharmacol; 2007 Aug; 74(3):383-91. PubMed ID: 17572390
[TBL] [Abstract][Full Text] [Related]
14. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding.
Bogoyevitch MA; Fairlie DP
Drug Discov Today; 2007 Aug; 12(15-16):622-33. PubMed ID: 17706543
[TBL] [Abstract][Full Text] [Related]
15. Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay.
Jahnke W; Grotzfeld RM; Pellé X; Strauss A; Fendrich G; Cowan-Jacob SW; Cotesta S; Fabbro D; Furet P; Mestan J; Marzinzik AL
J Am Chem Soc; 2010 May; 132(20):7043-8. PubMed ID: 20450175
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
[TBL] [Abstract][Full Text] [Related]
17. Chemical kinomics: a powerful strategy for target deconvolution.
Kim DH; Sim T
BMB Rep; 2010 Nov; 43(11):711-9. PubMed ID: 21110913
[TBL] [Abstract][Full Text] [Related]
18. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
19. Strategies for the identification of allosteric modulators of G-protein-coupled receptors.
Burford NT; Watson J; Bertekap R; Alt A
Biochem Pharmacol; 2011 Mar; 81(6):691-702. PubMed ID: 21184747
[TBL] [Abstract][Full Text] [Related]
20. Discovery and characterization of novel allosteric FAK inhibitors.
Iwatani M; Iwata H; Okabe A; Skene RJ; Tomita N; Hayashi Y; Aramaki Y; Hosfield DJ; Hori A; Baba A; Miki H
Eur J Med Chem; 2013 Mar; 61():49-60. PubMed ID: 22819505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
